Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Takeda Pharma News

    13,03 $ -0,31% -0,04 $
    In : 12,186 € | 26.04.24 22:10:00 NYSE aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1CWZF
    ISIN: US8740602052
    US-Symbol: TAK
    Typ: Aktie

    Takeda Pharma News

    23.04.24 - PR Newswire
    Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
    Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire
    22.04.24 - PR Newswire
    Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
    Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire
    27.03.24 - PR Newswire
    Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
    Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire
    27.03.24 - PR Newswire
    Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
    Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire
    26.02.24 - PR Newswire
    Championing Rare Voices on Rare Disease Day
    Championing Rare Voices on Rare Disease Day Canada NewsWire
    25.01.24 - PR Newswire
    Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
    Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation PR Newswire
    17.11.23 - PR Newswire
    The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
    The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of ...
    03.10.23 - PR Newswire
    Takeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
    Takeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data Canada NewsWire
    22.09.23 - PR Newswire
    Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
    Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 ...
    12.09.23 - PR Newswire
    Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge
    Patient-​led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge Canada NewsWire
    21.12.22 - PR Newswire
    Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
    Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire
    20.09.22 - PR Newswire
    Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infection
    Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-​Transplant Cytomegalovirus (CMV) infection Canada NewsWire
    14.09.22 - PR Newswire
    Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease
    Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease PR Newswire
    01.06.22 - PR Newswire
    NICE recommends Revestive® ▼ (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)
    NICE recommends Revestive® ▼ (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS) PR Newswire
    16.06.21 - PR Newswire
    Takeda Pharmaceuticals Marks its 240th Founding Anniversary
    Takeda Pharmaceuticals Marks its 240th Founding Anniversary PR Newswire
    16.06.21 - PR Newswire
    Takeda Pharmaceuticals Marks its 240th Founding Anniversary
    Takeda Pharmaceuticals Marks its 240th Founding Anniversary PR Newswire
    09.06.21 - PR Newswire
    Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community
    Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community PR Newswire
    09.06.21 - PR Newswire
    Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community
    Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community PR Newswire
    01.03.21 - PR Newswire
    The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases
    The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases A five-year commitment from Takeda will help ...
    08.02.21 - PR Newswire
    Rute Fernandes Appointed General Manager of Takeda Canada
    Rute Fernandes Appointed General Manager of Takeda Canada Canada NewsWire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »